0001415889-17-000282.txt : 20170216 0001415889-17-000282.hdr.sgml : 20170216 20170216190635 ACCESSION NUMBER: 0001415889-17-000282 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170214 FILED AS OF DATE: 20170216 DATE AS OF CHANGE: 20170216 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moore Terrence O CENTRAL INDEX KEY: 0001454276 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 17619385 MAIL ADDRESS: STREET 1: C/O ACADIA PHARMACEUTICALS INC STREET 2: 3911 SORRENTO VALLEY BLVD CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 form4-02162017_040225.xml X0306 4 2017-02-14 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001454276 Moore Terrence O 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO CA 92130 false true false false EVP, CHIEF COMMERCIAL OFFICER Common Stock 2017-02-14 4 M 0 87128 19.61 A 90759 D Common Stock 2017-02-14 4 S 0 89088 39.6863 D 1671 D Common Stock 2017-02-15 4 M 0 1700 19.61 A 3371 D Common Stock 2017-02-15 4 S 0 1700 39.65 D 1671 D Common Stock 2017-02-16 4 M 0 17421 19.61 A 19092 D Common Stock 2017-02-16 4 M 0 19687 27.20 A 38779 D Common Stock 2017-02-16 4 M 0 29644 34.45 A 68423 D Common Stock 2017-02-16 4 S 0 66752 39.8807 D 1671 D Stock Option (right to buy) 19.61 2017-02-14 4 M 0 12747 0 D 2023-08-18 Common Stock 12747 7649 D Stock Option (right to buy) 19.61 2017-02-14 4 M 0 74381 0 D 2023-08-18 Common Stock 74381 55223 D Stock Option (right to buy) 19.61 2017-02-15 4 M 0 1700 0 D 2023-08-18 Common Stock 1700 53523 D Stock Option (right to buy) 19.61 2017-02-16 4 M 0 17421 0 D 2023-08-18 Common Stock 17421 36102 D Stock Option (right to buy) 27.20 2017-02-16 4 M 0 19687 0 D 2024-03-06 Common Stock 19687 13125 D Stock Option (right to buy) 34.35 2017-02-16 4 M 0 29644 0 D 2025-03-19 Common Stock 29644 90356 D Includes 717, 1,243, 461 and 1,210 shares acquired in November 2014, May 2015, November 2015 and May 2016, respectively, by Mr. Moore under the ACADIA Pharmaceuticals Employee Stock Purchase Plan, as amended. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $39.72 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.38 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. 25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. 25% of the shares subject to the Stock Option vested and became exercisable on March 7, 2015. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. 25% of the shares subject to the Stock Option vested and became exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. /s/ Elizabeth Carter, Attorney-in-Fact 2017-02-16